Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 8-K (Current Report)
Date of Report: May 19, 2026
Reporting Period: Event-based report regarding legal proceedings.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a legal event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the status of a civil qui tam action initiated in February 2017 by a former employee (Relator) regarding the sale and promotion of the Company's product, Korlym®.
- DOJ Action: On May 19, 2026, the U.S. Department of Justice (DOJ) filed a Notice of Election to Decline Intervention in the lawsuit.
- Other Parties: The California Department of Insurance and named Plaintiff States also declined to intervene.
- Procedural Update: The Relator served an amended complaint on June 2, 2026.
Outlook, Risks, and Management Commentary
Management Commentary: The Company intends to vigorously defend against all of the Relator's claims.
Risks and Contingencies:
- Legal Contingency: The lawsuit concerns the Company's relationships with and payments to health care professionals, as well as prior authorizations and reimbursement for Korlym.
- Historical Context: The DOJ previously issued a records subpoena in November 2021 related to these matters, which the Company responded to in full.
- Forward-Looking Statements: The filing includes standard disclaimers that statements regarding the defense of the lawsuit involve risks and uncertainties and are based on current expectations.
Investor Verification Checklist
- Verify the specific allegations in the amended complaint served on June 2, 2026.
- Review the Company's most recent Form 10-K and 10-Q for historical disclosures regarding the 2017 lawsuit and the 2021 DOJ subpoena.
- Monitor future filings for updates on the litigation status and any potential financial impact or settlement discussions.
- Assess the potential impact on the commercialization and reimbursement of Korlym® should the litigation proceed to trial.